Lotte Chilsung Beverage (005300) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
23 Jun, 2026Executive summary
Q1 2025 consolidated sales declined 2.8% year-over-year to KRW 910.3 billion, with operating profit down 31.9% and net profit down 66.4%.
Beverage and liquor segments both saw sales and profit declines, but the liquor segment showed improved profitability and the beverage segment remained the largest contributor.
Overseas business posted sales growth but lower operating margins, with PCPPI (Philippines) revenue at KRW 254.2 billion.
Continued focus on zero-calorie and health-oriented products, with new launches planned for both beverage and liquor categories.
Financial highlights
Q1 2025 consolidated revenue: KRW 910.3 billion (down from KRW 936.9 billion YoY); operating profit: KRW 25.0 billion (down from KRW 36.8 billion YoY).
Net profit attributable to owners: KRW 7.0 billion (down from KRW 17.6 billion YoY); overall net profit: KRW 5.4 billion.
Gross profit margin decreased from 33.8% to 32.4% year-over-year.
Basic EPS: KRW 697 (down from KRW 1,748 YoY).
Cash and cash equivalents at period end: KRW 277.7 billion; current assets rose 12.3% sequentially.
Outlook and guidance
Full-year 2025 consolidated sales projected to rise 7.1% to KRW 4.31 trillion, with operating profit up 29.8% to KRW 240.0 billion.
Beverage and liquor sales expected to grow 2.1% and 2.7% respectively, with overseas sales up 16.5%.
Targeting a 30% shareholder return ratio on a consolidated basis by 2028, with plans for interim dividends and potential share buybacks.
Continued expansion in overseas markets, especially for zero-calorie and health-focused products.
New product launches and flavor revamps planned for key brands in 2025.
Latest events from Lotte Chilsung Beverage
- Q2 sales up 38.1% YoY, but net profit and margins fell as overseas drove growth.005300
Q2 202423 Jun 2026 - Sales and profits fell, but zero-calorie and health products drove segment growth.005300
Q3 202423 Jun 2026 - Profit growth in Q2 2025 driven by overseas and zero-calorie products, with strong full-year outlook.005300
Q2 202523 Jun 2026 - Profits and margins rose in Q3 2025, with overseas and health-focused products driving growth.005300
Q3 202523 Jun 2026 - Q1 2026 delivered sharp profit gains, margin expansion, and robust overseas segment growth.005300
Q1 202622 Jun 2026 - Domestic sales and profits fell in Q4 2025, but overseas growth and 2026 recovery are forecast.005300
Q4 20251 Apr 2026 - Record sales in 2024 offset by profit decline; 2025 targets strong growth and margin recovery.005300
Q4 20245 Jun 2025